

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: HATTORI=3

In re Application of:)	Conf. No.: Not Yet Known
)	
Kazuo HATTORI et al.)	Art Unit: Not Yet Known
)	
I.A. No.: PCT/JP2005/001764)	Examiner: Not Yet Known
I.A. filed: February 7, 2005)	
)	
U.S. Appln.No: Not Yet Known)	Washington D.C.
Filing Date: August 7, 2006)	
)	
For: 1- (2H) ISOQUINOLONE)	October 10, 2006
DERIVATIVE)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office,

either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.

3. Document AD is not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states that an English translation of each document AD (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.


4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Sheridan Neimark
Registration No. 20,520

SN:ma
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
g:\bn\y\yUAS\hATTORI 3\pTO\2006-10-10 IDS Form

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			I.A. Number	PCT/JP2005/001764	
			I.A. Filing Date	February 7, 2005	
			First Named Inventor	Kazuo HATTORI	
			Group Art Unit	Not Yet Known	
			Examiner Name	Not Yet Known	
Sheet	1	of	2	Attorney Docket Number	HATTORI=3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-4,942,163	07-17-1990	Carl H. BEHRENS	
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AB	WO 99/11624 A1	03-11-1999	GUILFORD PHARMACEUTICALS		
	AC	WO 98/51307	11-19-1998	OCTAMER, INC.		

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
	AD	Noboru YAGI et al., "Syntheses of N-Substituted-7-acylamino-3-phenylisocarbostyryl and 6-Phenylbenzimidazo[2,1-a]-isoquinoline Derivatives and their Fluorescence Spectra", <u>Yuki Gosei Kagaku Kyokaiishi</u> , Vol. 27, pp. 51-58, 1969.				Abs.
	AE	Won-Jea CHO et al., "Synthesis And Biological Evaluation of 3-Arylisoquinolines As Antitumor Agents", <u>Bioorganic & Medical Chemistry Letters</u> , Vol. 8, pp. 41-46, 1998.				
	AF	Alain ROSE et al., "Oxygen Heterocycles. Part XIII. ¹ From 3-Arylisoquinolines and 4-Aryl-5H-2,3-benzodiazepines", <u>J. Chem. Soc.</u> , (C), 1968, pp. 2205-2208.				
	AG	Graham S. POINDEXTER, "Convenient Preparation of 3-Substituted 1(2H)-Isoquinolinones", <u>J. Org. Chem.</u> , Vol. 47, pp. 3787-3788, 1982.				
	AH	Won-Jea CHO et al., "Synthesis and Antitumor Activity of 3-Arylisoquinoline Derivatives", <u>Arch. Pharm. Res.</u> , Vol. 20, No. 3, pp. 264-268, 1997.				
	AI	Seung Hoon CHEON et al., "Structure-Activity Relationship Studies of Isoquinolinone Type Anticancer Agent", <u>Arch. Pharm. Res.</u> , Vol. 24, No. 4, pp. 276-280, 2001.				
	AJ	Won-Jea CHO et al., "Molecular Modeling of 3-Arylisoquinoline Antitumor Agents Active Against A-549. A Comparative Molecular Field Analysis Study", <u>Bioorganic & Medical Chemistry Letters</u> , Vol. 10, pp. 2953-2961, 2002.				
Examiner Signature				Date Considered		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 2

Complete if Known

I.A. Number	PCT/JP2005/001764
I.A. Filing Date	February 7, 2005
First Named Inventor	Kazuo HATTORI
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	HATTORI=3

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AK	Thanh Nguyen LE et al., "A facile synthesis of benzo[c]phenanthridine alkaloids: oxynitidine and oxysanguinarine using lithiated toluamide-benzonitrile cycloaddition", <u>Tetrahedron Letters</u> , Vol. 45, pp. 2763-2766, 2004.	
	AL	Thanh Nguyen LE et al., "A Versatile Total Synthesis of Benzo[c]phenanthridine and Protoberberine Alkaloids Using Lithiated Toluamide-Benzonitrile Cycloaddition", <u>J. Org. Chem.</u> , Vol. 69, pp. 2768-2772, 2004.	
	AM	John P. WOLFE et al., "Simple, Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates", <u>J. Org. Chem.</u> , Vol. 65, pp. 1158-1174, 2000.	
	AN	Michele C. HARRIS et al., "Improved Functional Group Compatibility in the Palladium-Catalyzed Synthesis of Aryl Amines", <u>Organic Letters</u> , Vol. 4, No. 17, pp. 2885-2888, 2002.	
	AO	Xiaohua HUANG et al., "New Ammonia Equivalents for the Pd-Catalyzed Amination of Aryl Halides", <u>Organic Letters</u> , Vol. 3, No. 21, pp. 3417-3419, 2001.	
	AP	Kentaro OKANO et al., "Synthesis of Secondary Arylamines through Copper-Mediated Intermolecular Aryl Amination", <u>Organic Letters</u> , Vol. 5, No. 26, pp. 4987-4990, 2003.	
	AQ	Artis Klapars et al., "A General and Efficient Copper Catalyst for the Amidation of Aryl Halides and the N-Arylation of Nitrogen Heterocycles", <u>J. Am. Chem. Soc.</u> , Vol. 123, pp. 7727-7729, 2001.	
	AR	Artis Klapars et al., "A General and Efficient Copper Catalyst for the Amidation of Aryl Halides", <u>J. Am. Chem. Soc.</u> , Vol. 124, pp. 7421-7428, 2002.	
	AS	Teruo UMEMOTO et al., "Synthesis, Properties, and Reactivity of N,N-Difluoribipyridinium and Related Salts and Their Applications as Reactive and Easy-To-Handle Electrophilic Fluorinating Agents with High Effective Fluorine Content", <u>J. Org. Chem.</u> , Vol. 63, pp. 3379-3385, 1998.	
	AT	J. Hodge MARKGRAF et al., "Strained Heterocyclic Systems. 16. ¹ 1-Azatrypticene", <u>Heterocycles</u> , Vol. 29, No. 4, pp. 649-651, 1989.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.